Open AccessApplicability of mitochondrial energy factors in accompanying therapy of lymphoproliferative diseases (experimental study)
Author(s) -
Valeria A. Bandovkina,
Lidia K. Trepitaki,
Ekaterina I. Surikova,
И.В. Нескубина,
Juliya Pogorelova,
Natalia D. Cheryarina,
Alla I. Shikhlyarova,
Т. И. Моисеенко,
M.N. Duritskii,
S.V. Tumanian,
Yuriy V. Przhedetskiy,
Viktoria V. Pozdnyakova
Publication year - 2021
Publication title -
cardiometry
Language(s) - English
DOI - 10.18137/cardiometry.2021.20.2933
Subject(s) - saline , drug , cytochrome c , medicine , pharmacology , gastroenterology , physiology , immunology , pathology , biology , mitochondrion , biochemistry
Aim. The purpose of the study was to reveal the effectivenessof the Cytochrome C drug in the early stages of the Pliss lymphosarcomagrowth in white outbred rats.Material and methods. The studies were included white outbredmale rats with an initial weight of 180–220 g (n = 40) withsubcutaneously inoculated Pliss lymphosarcoma. Rats in themain group received the Cytochrome C intraperitoneally in asingle dose of 1.6 mg/kg 1 hour after the tumor inoculationand then until death; animals with tumors in the control groupreceived saline instead of the studied drug in the same way andin the same dosage.Results. Subcutaneous tumors appeared in the control groupin 100% cases, in the main group in 55% cases; tumors werenot detected in 45% of animals in the main group. In rats ofthe main group receiving experimental treatment, tumors regressedwith time: in 73% cases with complete recovery of rats,in 27% cases animals died.Conclusions. The Cytochrome C in a therapeutic and prophylacticregimen had a pronounced antitumor effect. Perhaps theeffectiveness of the drug can be improved using an inert carrierwhich will protect the protein from proteolytic cleavage whenit enters the bloodstream, together with detoxification agents.